CardioGenics Holdings Inc. (CGNH)

[rambler]

Also important click on link for medical publication putting Cardiogenics alongside the names of Roche, Siemens, Johnson&Johnson and Abbot and you will understand why the biggest pharmaceuticals in the world are looking very closely at this company!!!

CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
Wed Oct 6, 9:00 AM
Email Story IM Story Printable View

MISSISSAUGA, Ontario, Oct. 6 /PRNewswire/ -- Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH.OB), has authored a cover story for this month's Medical Device & Diagnostic Industry Magazine (MD+DI) which addresses improvements in diagnostic times using point-of-care technology. In the article, titled "Improving Diagnosis Times with New Point-of-Care Technology," Dr. Gawad reviews the in-vitro diagnostics market and the growth of point-of-care testing.

In addition to reviewing other point-of-care devices, Dr. Gawad describes the operation of the QL Care Analyzer(TM), CardioGenics' point-of-care immunoassay platform that will allow a heart attack diagnosis to be made in as little as 15 minutes vs. the national average of 2.8 hours required for test results from a central lab. CardioGenics expects to submit to the FDA a 510K application for the QL Care Analyzer(TM) (and its first cardiac test, Troponin-I) during Q1 2011 and to have both commercialized by Q2 2011.

The article can be accessed online at:

http://www.mddionline.com/article/im...are-technology

About Medical Device & Diagnostics Industry

Medical Device & Diagnostic Industry is a leading monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnostic products. The goal of MD&DI is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. MD&DI is published 12 times each year, along with two additional issues of its Guide to Outsourcing supplement.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care(TM) Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.